Clinical Research Directory

Browse clinical research sites, groups, and studies.

3 clinical studies listed.

Healthy volunteers

Filters:

Blasts More Than 5 Percent of Bone Marrow Nucleated Cells

Tundra lists 3 Blasts More Than 5 Percent of Bone Marrow Nucleated Cells clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT04049539

Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction

This phase II trial studies the side effects and how well Vyxeos works in treating patients with intermediate and high-risk acute myeloid leukemia who have failed an initial cycle of standard cytarabine and daunorubicin chemotherapy. Vyxeos is a combination of both chemotherapy drugs cytarabine and daunorubicin contained in a liposome. Drugs used in chemotherapy, such as cytarabine and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cytarabine and daunorubicin given together in liposomes may have fewer side effects and work better than cytarabine and daunorubicin given alone in patients with acute myeloid leukemia.

Gender: All

Ages: 18 Years - 75 Years

Updated: 2026-04-08

2 states

Blasts More Than 5 Percent of Bone Marrow Nucleated Cells

Persistent Disease

Refractory Acute Myeloid Leukemia

RECRUITING

NCT03896269

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

This phase I trial studies best dose and side effects of liposome-encapsulated daunorubicin-cytarabine (CPX-351) and how well it works in treating patients with high risk myelodysplastic syndrome or chronic myelomonocytic leukemia that has come back or has not responded to treatment. Drugs used in chemotherapy, such as liposome-encapsulated daunorubicin-cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Gender: All

Ages: 18 Years - Any

Updated: 2026-02-20

1 state

Blasts 10-19 Percent of Bone Marrow Nucleated Cells

Blasts More Than 5 Percent of Bone Marrow Nucleated Cells

High Risk Chronic Myelomonocytic Leukemia

RECRUITING

NCT03801434

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

This phase II trial studies how well ruxolitinib works in treating patients with hypereosinophilic syndrome or primary eosinophilic disorders.

Gender: All